ProNoxis AB Raises SEK 4 Million in Directed New Share Issue.
(Thomson Reuters ONE) -
April 30, 2011 with operations proceeding as planned, ProNoxis AB has secured
SEK 4 million in a new round of financing. Signalling confidence in ProNoxis
development to date, lead investor LU Bioscience invested SEK 2.5 million and
Karolinska Development SEK 1.5 million. They now hold 29.7 and 17.6 percent of
ProNoxis, respectively. Redoxis AB holds the remaining 52.7 percent. At the end
of last year, ProNoxis strengthened the board of directors with the appointments
of Tomas Leanderson and Ulf Björkman, who both have extensive industry
experience.
For more information, please contact:
Karin Bryder, CEO ProNoxis,karin.bryder(at)pronoxis.com, +46 70 755 69 00
Thomas Andersson, CEO LUBio,thomas(at)lubio.se, +46 70 287 00 15
About LU Bioscience AB
Lund University Bioscience AB (LUBio) transforms high-end research results and
innovations into attractive business propositions by integrated support for
researchers. LU Bio is an early-stage investor providing both capital and
industrial development expertise to enable rapid and efficient development of
bioscience inventions.www.lubio.se
About ProNoxis AB
ProNoxis AB was founded in 2009 by LU Bioscience AB (LUBio), Karolinska
Development AB, and Redoxis AB, as a Redoxis spin-off focusing on developing
anti-inflammatory therapeutics targeting activation of the NADPH oxidase complex
(NOX2). ProNoxis focuses on the development of small-molecule drugs to treat
chronic inflammation.
www.pronoxis.com
About Karolinska Development
Karolinska Development aims to create value for investors, patients, and
researchers by developing and transforming world-class research innovations into
high-return products. The business model is to SELECT the most commercially
attractive medical innovations; DEVELOP these to the stage where the greatest
return on investment can be achieved; and COMMERCIALIZE the innovations through
the sale of companies or licensing of products. This results in upfront
payments, milestone payments, and royalties.
www.karolinskadevelopment.com
About Redoxis AB
Founded in Sweden in 2007, Redoxis provides contract research organization
services in preclinical drug validation based on in vitro and in vivo autoimmune
inflammation models. Redoxis focuses on preclinical development of small
molecules that target molecular pathways in the immunological responses
associated with autoimmune diseases such as Rheumatoid Arthritis (RA) and
Multiple Sclerosis (MS).
www.redoxis.com
Press Release (PDF) :
http://hugin.info/141955/R/1524003/459883.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: LU Bioscience via Thomson Reuters ONE
[HUG#1524003]
Unternehmensinformation / Kurzprofil:
Datum: 17.06.2011 - 09:00 Uhr
Sprache: Deutsch
News-ID 55646
Anzahl Zeichen: 3390
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 215 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ProNoxis AB Raises SEK 4 Million in Directed New Share Issue."
steht unter der journalistisch-redaktionellen Verantwortung von
LU Bioscience (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
